Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allurion Technologies Inc ALUR

Alternate Symbol(s):  ALUR.WS

Consumer Cyclical Personal Services
Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform and health tracker devices. Its health tracker devices include Allurion... see more

Recent & Breaking News (NYSE:ALUR)

Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies

Business Wire January 29, 2024

World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss

Business Wire January 23, 2024

Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships

Business Wire January 17, 2024

Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities

Business Wire January 11, 2024

Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook

Business Wire January 8, 2024

New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

Business Wire January 5, 2024

Allurion's Digital Platform Gains Traction with Expanded Strategic Partnership

Business Wire January 2, 2024

Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update

Business Wire November 13, 2023

Allurion to Participate in the Jefferies London Healthcare Conference

Business Wire November 6, 2023

Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023

Business Wire November 6, 2023

Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon

Business Wire October 11, 2023

Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023

Business Wire October 4, 2023

Allurion Featured at the 2023 International Bariatric Club Oxford University World Congress

Business Wire September 18, 2023

Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach

Business Wire August 29, 2023

Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress

Business Wire August 28, 2023